Today: 11 January 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

LivePerson (LPSN) Soars After Citron Shout‑Out: Q3 Beat, Guidance Lift, and AI ‘Conversation Simulator’ Fuel Rally — 11/11/2025

LivePerson (LPSN) Soars After Citron Shout‑Out: Q3 Beat, Guidance Lift, and AI ‘Conversation Simulator’ Fuel Rally — 11/11/2025

LivePerson, Inc. (NASDAQ: LPSN) jumped sharply on Tuesday after a bullish note from Citron Research added fuel to momentum from the company’s third‑quarter results released late Monday. As of mid‑afternoon, shares traded near $6.25 and touched an intraday high of
11 November 2025
····
The RealReal (REAL) spikes to new highs after Q3 beat; Wall Street lifts targets to $15–$16 — all the news investors need today (Nov. 11, 2025)

The RealReal (REAL) spikes to new highs after Q3 beat; Wall Street lifts targets to $15–$16 — all the news investors need today (Nov. 11, 2025)

The luxury resale leader topped Q3 estimates Monday and raised guidance. By Tuesday, shares hit fresh 52‑week highs as BTIG, UBS, Northland, KeyBanc and Baird updated calls. The RealReal, Inc. (NASDAQ: REAL) extended Monday evening’s earnings momentum into Tuesday’s session,
11 November 2025
····
Tesla (TSLA) Today — Nov. 11, 2025: China Sales Sink to 3‑Year Low, Model Y & Cybertruck Chiefs Exit, as Musk’s AI Pivot Takes Center Stage

Tesla (TSLA) Today — Nov. 11, 2025: China Sales Sink to 3‑Year Low, Model Y & Cybertruck Chiefs Exit, as Musk’s AI Pivot Takes Center Stage

On Nov. 11, 2025, Tesla’s China sales hit a three‑year low, two vehicle‑program leaders departed, shareholders’ $1T Musk award reverberated, and fresh commentary put Optimus and FSD ambitions back in the spotlight. TSLA slips intraday. TSLA stock snapshot (intraday) As
11 November 2025
····
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

What happened today Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) announced that it has successfully achieved target loading concentrations for two topical rapamycin delivery technologies—4% in its lotion and 5% in a dermal patch. The company said it will start manufacturing clinical
11 November 2025
···
1 … 53 54 55 56 57 … 232
Go toTop